Physicochemical and pharmacological evaluation of carvedilol-eudragit® RS100 electrospayed nanostructures

Sevil Selselehjonban 1, 2, Alireza Garjani 3, Karim Osooli-Bostanabad 1, 2, Ali Tanhaei 1, Shahram Emami 1, Khoosro Adibkia ***, Mohammad Barzegar-Jalali 1

1 Research Center for Pharmaceutical Nanotechnology, Biomedicines Institute, Tabriz University of Medical Sciences, Tabriz, Iran
2 Students Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
3 Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
4 Pharmaceutical Analysis Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran

ABSTRACT

Objective(s): This study was carried out to boost the pharmacologic influence of carvedilol (CAR) (as a poorly water-soluble drug) by developing CAR-eudragit® RS100 (Eud) nanofibers and nanobeads benefiting an electrospaying approach.

Materials and Methods: CAR-Eud nanoformulations with varying ratios (1:5 and 1:10) at total solution concentrations of 10 %, 15 % and 20 % w/v were formulated.

Results: The solution concentration remarkably impressed the size and morphology of the samples; in which, the nanobeads (mean diameter of 135.83 nm) were formed at low solution concentrations and high concentrations led to nanofibers (mean diameter of 193.45 nm) formation. DSC thermographs and PXRD patterns along with FTIR spectrum precisely showed CAR amorphization and no probable chemical interactions between CAR and Eud in the electrospayed nanosystems. The in vitro release considerations demonstrated that the nanoformulations with the drug: polymer ratios of 1:10 and 1:5 depict rapid dissolution rate compared to the physical mixtures (PMs) and the pure drug. The in vivo studies in Wistar male rats suggested that the electrospayed nanoformulation (1:10; 20 %) reduced the isoproterenol (ISO) induced elevation of heart rate, nerosis and accumulation of neutrophils in the heart tissue more efficient than the pure drug and PM.

Conclusion: Our finding illustrated that the electrospaying as a profitable one-step procedure could be productively benefited to improve the physicochemical features and pharmacologic influences of CAR.

Introduction

Cardiovascular (CVD) and coronary artery diseases (CAD) such as myocardial infarction (MI) are the first leading cause of the global mortality (31 % of worldwide deaths) based on the World Health Organization (WHO) report (1). Carvedilol (CAR) (an antihypertensive substance with nonselective α and β blocking behaviors) have been broadly prescribed to treat MI, hypertension, heart failure (HF)/ congestive HF and patients with systolic dysfunction after MI (2). CAR the 3rd generation β blocker offers multiple advantages (i.e. cardioprotection, vasodilatation, anti-proliferation, antioxidiant, anti-arrhythmic and metabolic actions) because of its nitric oxide dependent characteristics. However, CAR is a class II drug based on biopharmaceutical classification system (BCS) with low aqueous solubility and consequently poor oral bioavailability (around 25–35 %) (3). These drawbacks (i.e. low oral bioavailability and poor aqueous solubility) are associated with 40 % of newly discovered active pharmaceutical ingredients (APIs) as reported in literature (4). So, different methods, including cyclodextrin complexation (5, 6), solid dispersion (7), cocystallization (8), nanoemulsion (9, 10), liquisolid (11) and salt formation (12) have been developed to enhance solubility and consequently the bioavailability of such APIs. Nowadays, drug loaded nanoparticles (NPs) have been considered as the most attractive drug delivery systems (DDSs) with ability of delivering a precise dose of drugs to the action site and enhancing therapeutic effect alongside decreasing patient compliance and drug toxicity (13-16). Furthermore, these controllable and suitable carriers can significantly improve the APIs dissolution rate due to the particle size reduction (Noyes–Whitney equation) which in turn could lead the drug bioavailability enhancement. Various inorganic, organometallic and organic compounds such as polymers, liposomes, lipids, micelles and viruses properly have been used to design applicable API nanoparticles with enhanced functionality. The polymer based NPs (PNBPs) and drug entrapment in these PBNPs are growing interest of new drug formulation systems (17, 18). In comparison with the conventional drug formulations, better delivery control can be achieved using the drug entrapped PBNPs. Many strategies such as an aerosol flow reactor, supercritical fluid (19), solvent evaporation/emulsification (13), template synthesis (20) and electrospaying/electrospinning (20-22) have been advanced to produce the PBNPs.

Recently, numerous attempts have been made for

**Corresponding author: Khoosro Adibkia. Pharmaceutical Analysis Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. Tel/Fax: +98-4133344798; Email: adibkia@tbzmed.ac.ir
manufacturing appropriate micro-nanoscale beads or fibers by electrohydrodynamic or electrospraying method to be exploited in DDSs, optoelectronics, microelectronic, tissue engineering, etc. (21-23). This method atomizes a compound of a polymer-drug solution using a high voltage (i.e. 20-30 kV) applied to a syringe (capillary nozzle) (20, 23). The high electrical force and consequently electrostatic charge build-up on the tip of the nozzle cause a shape change in the solution interface. Enhancing the electrical potential leads to increase of the electrostatic forces and as a consequence reduces the surface tension effect on the interface shape at the nozzle tip and the Taylor cone forms once a balance between the two forces is achieved. The cone will break into droplets with smaller sizes if further charge disturbs the cone tip. Flow rate, conductivity, viscosity and surface tension, are the parameters that affect the size of resulted droplets. Normally, fiber formation predominated when the viscoelastic forces overcome the surface tension due to the solution concentration enhancement in electrospraying procedure (23). The electrospray produces a highly charged liquid jet, which moves out towards a grounded screen/counter electrode in the high voltage electrical field. During the jet flying, solvent evaporates and drug encapsulated nanofibers or nanobeads are developed based the polymer-drug solution viscosity (23). By applying this one-step method at ambient pressure and temperature, nanosystems with high throughput, negligible drug loss, high loading capacity and uniform drug dispersion inside the polymeric matrix can be achieved. Ability of controlling the quality of sprayed nanobeads and nanofibers; capability of spraying the most of polymers without changing the basic setup of the process; cost effectiveness and ease of operation are the other valuable aspects of this method (24). Some drugs, such as propranolol hydrochloride (23), insulin (25), triamcinolone acetonide (26), paclitaxel (27), ibuprofen (28), azithromycin (29), naproxen (30) and methylprednisolone acetate (31) have been successfully processed using this method.

Eudragit® RS100 (Eud) is a hydrophilic water-insoluble copolymer of poly (ethylacrylate, methylmethacrylate and chlorotrimethyl-aminomethylethyl methacrylate) containing quaternary ammonium groups (4.5-6.8 %). Some exclusive properties such as good stability, no toxicity, swelling ability in aqueous media and high permeability make it a suitable candidate for drug loading purposes which represents the good material for the drug dispersion. These characteristics may subsequently maximize the cellular uptake of drug–polymer complex. Eud has been previously applied for delivery as well as increasing the bioavailability of several drugs (13, 23, 26, 29, 31). Furthermore, our previous studies showed that Eud has good characteristics and processability for applying in electrospraying technique (13, 23, 26, 29, 31). Although there are some reports regarding preparation of CAR electrosprayed fibers using various polymers such as eudragit® L 100-55 (poly (methacrylic acid-co-methyl methacrylate)), eudragit® E (poly (butyl methacrylate-co-(2 demethylaminoethyl) methacrylate co methyl methacrylate) (32), eudragit® EPO (poly (butylmethacrylate-co (2 dimethylaminoethyl) methacrylate co methyl methacrylate) 1:2:1) (32, 33), polycaprolactone, polyvinylpyrrolidone K90 (32) and copolymer of vinylpyrrolidone-vinyl acetate (kollidon® VA64) (34), despite that, to the best of our knowledge, there is no report regarding the CAR- Eudragit® RS100 electrosprayed nanosystems preparation and their in vivo characterization.

In this study, we focused on the CAR-Eud nanosystems development in order to improve the physicochemical characteristics as well as the pharmacological effect of CAR. To this end, CAR- Eud nanobeads and nanofibers were formulated using the electrospraying method with different drug to polymer ratios at various solution concentrations. The prepared nanosystems were assessed for the morphological and physicochemical behaviors. Furthermore, we made special focus on pharmacological effects of the prepared nanosystems in Wistar male rats.

**Materials and Methods**

**Materials**

Eudragit® RS100, Carvedilol and isoproterenol were obtained from Degussa (Darmstadt, Germany), Salehanchemi (Tehran, Iran) and Sigma-Aldrich (USA), respectively. Sodium hydroxide, ethanol and potassium phosphate monobasic were purchased from Merck (Germany). All other chemical materials were analytical grade.

**Electrospraying samples preparation**

A custom-designed electrospraying apparatus (Fanavar Nano-Meghyas, Tehran, Iran) was operated to formulate CAR-Eud samples. Briefly, CAR-Eud solutions with 1:5 and 1:10 drug: polymer ratios were developed by co-dissolving CAR and Eud in ethanol at ambient condition. The drug: polymer solution total concentrations were regulated to be 10, 15 and 20 % (w/v).

The liquid stream (jet) of formulated solutions was shaped by utilizing a voltage of 25 kV connected to the syringe tip (gauge 29) attached to a ring shaped capillary polyethylene vessel with internal diameter of 0.1 mm. The processed solutions were streamed upon a grounded polytetrafluoroethylene coated aluminum, as a collector screen to produce CAR-Eud systems. The injection rate and distance between the grounded screen and nozzle tip were fixed at 5 ml/hr and 10 cm, respectively. In this study a piece of an inert and rigid thermoset polymer with a sharp edge was used to collect the sprayed formulations from the surface of the collector screen in order to do further studies. Furthermore, the tumbling bottle technique was applied to prepare the corresponding physical mixtures, where the tumbling time was set to be one hour in a 100 ml bottle to attain homogeneous PMs.

**Field emission scanning electron microscopy (FE-SEM)**

The field emission scanning electron microscope (MIRA3, Tescan Co, Brno, Czech) acting at 20 kV was benefited to assay the processed specimens morphology. Prior to investigate, a thin gold film was used to coat the electrosprayed formulations (about 150 Å in thickness) using gold sputtering machine.
(Emitech K550, Kent, UK). The average diameters of electrosprayed samples were estimated directly from FE-SEM images by calculating the samples diameters at above 50 points applying Digimizer image analysis software. The assessed diameters were illustrated as “mean Feret diameter±standard deviation”. A particle size measurement along a particular direction is called the Feret/Feret’s diameter. Generally, it can be described as the space between two parallel tangential lines that perpendicularly limits the particle to that direction. This method is applied to measure particle sizes in microscopy, where a 3-dimensional particle is projected on a 2-dimensional plane (7, 32, 35).

**Differential scanning calorimetry (DSC)**

The thermograms and thermal behaviors of pure CAR, Eud, physical mixture (PM) and electrosprayed formulations were studied conducting DSC 60 (Shimadzu, Kyoto, Japan). Briefly, at first 5 mg of each processed sample was meticulously weighed and placed in sealed aluminum pans, then the thermal attitudes were investigated at a scan rate of 20 °C/min (25-220 °C) and analyzed by TA60 software. The indium and aluminum oxide powders were served as standard and reference models, respectively.

**Fourier transform infrared spectroscopy (FTIR)**

The FTIR spectrophotometer (Shimadzu 43000, Kyoto, Japan) was utilized to justify the chemically probable interactions of drug-polymer. Briefly, a compact disc of pure CAR, Eud, CAR-Eud PM and their electrosprayed specimens were manufactured by KBr disk approach and assessed at scanning range of 4000-400 cm⁻¹ with average spectra of 32 scans at a resolution of 2 cm⁻¹.

**Powder X-ray diffraction (PXRD)**

PXRD patterns of pure CAR, Eud, PM and electrosprayed samples were achieved employing X-ray diffractometer D5000 (Siemens, Munich, Germany) at 20 angle range, scanning rate and step size of 10°-40°, 0.6 °/min and 0.02°, respectively by Kα radiation of Cu (λ=1.5405 Å) at 40 kV, 30 mA.

**In vitro drug release**

The dissolution characteristics of pure CAR, PM and electrosprayed samples were studied using USP apparatus II (paddle method). Briefly, samples equivalent to 20 mg of CAR under rotational agitating (50 rpm) were situated in the container with 300 ml of phosphate buffer (pH 6.8) at 37±0.2 °C. At predetermined intervals, 3 ml of the treated solutions was removed and replaced with the same amount of fresh buffer in order to retain an unvarying volume. The cellulose acetate membrane (pore size 20 nm, Whatman, Kent, UK) was utilized to filter the carried away solution. UV spectrophotometer (Shimadzu, Kyoto, Japan) at a wavelength of 285 nm was conducted to estimate the drug cumulative release graphs. The average values of three assessments were used.

**Animal study**

**Animals**

A total of 30 male Wistar rats (250-300 g) was supplied by Animal Center Laboratory, Tabriz University of Medical Sciences, Iran. Animals were housed under specific conditions of 12-12 hour light to dark cycle in an air conditioned room at 20±2 °C with a relative humidity of 50±10%. Food (UAR, Villemoisson sur Orge, France) and water were supplied ad libitum. All animal procedures were performed according to the ‘Guide for the Care and Use of Laboratory Animals’ of the research center for Laboratory Animal of Tabriz University of Medical Sciences which is in accordance with the National Institutes of Health guidelines (revised 2011) and was approved by the local authorities of Animal Ethics Committees (AEC reference number: IR.TBZMED.REC.1395.1337).

**In vivo procedure**

Healthy adult rats were randomly allocated into 6 groups consisting of 5 rats each. Rat in all groups were gavaged orally either saline or formulations for six consecutive days. Animals in group I (Control (Sal+Sal)) were injected sterile saline (0.5 ml) subcutaneously (SC) for two days and then were gavaged 0.5 ml sterile saline solution for the last four days. Rats in group II (ISO+Sal) were injected isoproterenol (ISO) (100 mg/kg; SC) for two days with an interval of 24 hours and subsequently were gavaged 0.5 ml saline the same as the group I for last four consecutive days. Animals in group III (Sal+PM) were received SC injection of sterile saline in two starting days and then were given orally CAR-Eud physical mixture (2 mg/kg; CAR) in the last four days. Rats in groups IV (Sal+Es) were injected sterile saline (0.5 ml, SC) for two days plus were gavaged CAR-Eud electrosprayed formulations (drug: polymer ratio of 1:10 and total solution concentration of 20 %) for the last 4 days. Rats in groups V (ISO+PM) were injected ISO (100 mg/kg) for two consecutive days and were gavaged PM the same as the group III. Rats in groups VI (ISO+Es) were received SC injection of ISO (100 mg/kg) for two days and then were given CAR–Eud electrosprayed formulations orally the same as the group IV.

On the sixth day, 2 hours after the last gavage the animals were anesthetized by IP injection of ketamin (400 mg/kg) plus 40 mg/kg xylazin. Then, when rats, no longer responded to external stimuli the standard limb lead II electrocardiogram (ECG) was recorded using POWERLAB system (AD instruments, Australia) for evaluating the heart rate (HR), ST-Segment and R wave amplitude. Table 1 summarizes the in vivo procedure of the current study.

In the current study, all the gavaged samples were prepared freshly and immediately before administration using mild ultrasonic vibration for only three seconds that resulted in a very homogenous dispersion of the electrosprayed sample in sterile saline solution. As mentioned previously, Eud is a hydrophilic water-insoluble copolymer that its hydrophilicity helps achieving a homogenous dispersion of the electrosprayed formulation.

**Histopathological evaluation**

In order to carry out the histopathological evaluation, the apex of the dissected hearts was separated and kept at 10 % buffered formalin. Afterwards, the fixed parts
were embedded in paraffin, sectioned (5-6 μm thick) and stained by hematoxylin and eosin for regular tissue assessing. Histopathological evaluations, i.e. neutrophils, myocyte necrosis, and edema were accomplished in the blinded way under the BX50 light microscope (Olympus, Tokyo, Japan). The degree of histopathological changes for each of the layers was scaled from 1 to 4: (1) low, (2) mild, (3) moderate and (4) severe injury.

**Statistical analysis**

One way ANOVA, which followed by a Student–Newman–Keuls post-test was applied to compare the groups. Statistical analysis was implemented using Sigmaplot V12 and any variations among the groups were assumed significant at $P<0.05$ levels. The *in vivo* data were asserted as mean±SEM and attained from five experimented rats.

**Results**

**Morphological evaluation of electrosprayed samples**

Figure 1 shows the morphology and size of CAR-Eud electrosprayed systems. As it is clear from the FE-SEM results, the nanobeads in concave shape were formed at lower solution concentrations, so that the average particles size were $237.66±54.17$ nm and $369.97±108.01$ nm for the nanobeads with drug: polymer ratios of 1:5 and 1:10 (total solution concentration of 10% w/v), respectively (Figure 1A, D). Enhancing the solution concentration led to formation of the nanofibers with smooth surfaces at both 1:5 and 1:10 drug: polymer ratios (Figure 1C, E, F). The corresponding average diameters were $80.64±10.90$ nm (1:10; 15% (w/v)), $98.64±13.26$ nm (1:5; 20% (w/v)) and $193.45±96.57$ nm (1:10; 20% (w/v)). It is worth to note that, the electrosprayed sample with drug: polymer ratio of 1:5 with a total solution concentration of 15% (w/v) (i.e. a moderate concentration) (Figure 1B) resulted a blend of nanobeads ($512.99±85.91$ nm) and nanofibers ($104.24±6.76$ nm).

**Differential scanning calorimetry**

The thermal behavior of pure CAR, Eud, PM and electrosprayed nanosystems were examined by DSC (Figure 2A). A sharp endothermic peak at 117 °C was related to the melting point of CAR (33), where Eud showed an amorphous attitude (glass transition...
temperature of 58.44 °C (23, 26). The melting peak of CAR was not detected in the electrosprayed nanosystems, suggesting occurrence of one or more of the following events: the drug amorphization; heat induced interaction between CAR and Eud; and the drug solubilization in the polymer. Moreover, the PM of CAR and Eud showed the endothermic peak of the drug with a diminished intensity and a slight shift due to the solubilization of CAR in melted Eud and/or dilution effect of Eud and/or heat induced interaction between CAR and Eud (8, 23).

Powder X-ray diffraction (PXRD) evaluation

The crystallinity of the pure drug, Eud, PM and electrosprayed samples were identified using X-ray diffractometer (Figure 2B). The sharp, distinctive diffraction peaks at 2θ angles of 12.8°, 15.62°, 17.46°, 18.56°, 20.1°, 24.3° and 26.2° were demonstrated the crystalline characteristics of pure CAR (32, 34, 36). The absence of any characteristic peaks in the PXRD curve of Eud revealed its amorphous behavior. The PXRD pattern of PM showed the characteristic peaks of CAR with a reduced intensity due to the possible dilution effect of Eud (37). Although, CAR preserved its crystalline structure in the PM; however, no distinctive diffraction peak was indicated in the PXRD patterns of CAR-Eud electrosprayed nanosystems, suggesting CAR transformation to an amorphous form during the preparation process.

Fourier transform infrared spectroscopy

The FTIR spectrophotometer was applied to detect the possibility of any drug-polymer chemical interactions in the solid state (Figure 3). The FTIR spectrum of CAR displayed distinctive peaks at 3344.66 cm⁻¹ (N-H and O-H stretching peaks combined together), 2924.86 cm⁻¹ (C-H stretching), 2840.56 cm⁻¹ (C-O stretching), 1594.90 cm⁻¹ (N-H bending vibrations), 1255.39 cm⁻¹ (C-O stretching and O-H bending vibrations) and 1029.54 cm⁻¹ (symmetric C-O-C stretching) (33, 36, 38). Moreover, FTIR spectra of pure Eud indicated the peaks at 2991.35 cm⁻¹ (CH aliphatic stretching) and 1732.64 cm⁻¹ (-C=O stretching) (23, 26).

The PM FTIR spectra clearly revealed the drug and polymer characteristic absorption bands, demonstrating presence of CAR and Eud. Additionally, CAR and Eud typical bands were detectable in the FTIR spectrum of the electrosprayed formulations, illustrating the retention of CAR chemical identity. However, CAR peaks intensity was decreased or the peaks were broadened in the prepared formulations, probably because of the crystallinity loss or the dilution effect of the polymer and physical entrapment of the drug within the polymer matrix especially at high solution concentrations. These findings are in good conformity with DSC and PXRD results and other relevant reports (29, 31, 38).

In vitro dissolution study

The drug release profiles of pure CAR, PMs and electrosprayed nanosystems were assessed using USP apparatus II (paddle method) (Figure 4). The effect of electrospraying procedure and the polymer ratio on the drug release behavior were assessed by calculating t₂₅% (the time needed for 25% of the drug release), Q₁₅min and Q₃₀min values (relevant percent of the dissolved drug during 15 and 30 min, respectively) are illustrated in Table 2.

Considering the t₂₅%, Q₁₅min and Q₃₀min values at a
specified pH, it can be concluded that the electrosprayed nanosystems had meaningfully faster drug release rate than the PMs and pure drug. So that, $Q_{15\text{min}} = 33.3\%$ and $Q_{30\text{min}} = 50.3\%$ were determined for the nanoformulations with the drug: polymer ratios of 1:10 at total solution concentration of 20 $\%$ (w/v), while the corresponding values were estimated to be $3.0\%$ and $7.6\%$ for the crystalline CAR.

The dissolution curves (Figure 4) depicted a relatively biphasic release pattern; so that the initial rapid release within the first hours followed by the slow release. Drug encapsulation on the superficial layers of the particles as well as the high specific surface area due to the smaller size of the nanobeads and nanofibers are two phenomena which could explain the rapid release; while, the diffusion and dissolution of the drug from inner layers elucidated plateau phase (23, 29). Altogether, electrosprayed formulations showed enhanced drug release compared to the pure drug and PMs, but it was demanding to explain the mechanism of drug release and randomness of release patterns. Hence, scrutinizing the exact reason of the observed release behaviors needs to conduct further studies. However, by considering the aim of this study, that was improving the pharmacologic influence of carvedilol (as a poorly water-soluble drug), the fastest release rate of the electrosprayed sample with the drug: polymer ratio of 1:10 at the total solution concentration of 20 $\%$ (w/v) made it an appropriate system for the in vivo delivery of CAR.

**In vivo study**

In the present study, maximum effect on heart rate was induced two hours after the last injection of ISO. In vivo effectiveness of the CAR-Eud electrosprayed nanosystems were compared with that of the PM and pure CAR by assessing their effects on ECG parameters, incidence of the necrosis and edematous in the heart tissue of the rats. It is mentioned that the hypotension is a pleiotropic effect of carvedilol because of the relative blockage of vascular α receptors (39, 40), but there is not clear and measurable (at least in the experiential model of this study) as well as an immediate action of the drug. Carvedilol mainly is a beta blocker and its original and real pharmacological effects appear on the heart. Therefore, the ECG parameters were evaluated in this study. Table 3 summarizes the data of recorded ECG parameters in the different rat groups.

As shown in Table 3, the heart rate was increased concentration of 20 $\%$, while the corresponding values were estimated to be $3.0\%$ and $7.6\%$ for the crystalline CAR.
from (238±5) in normal control rats (sal+sal) to 
(283±28 beats/min) in the group injected ISO 
(ISO+sal). Administration of CAR–Eud electrosprayed 
nanoformulations (drug: polymer ratios of 1:10 at the 
total concentration of 20 % w/v (2 mg/kg; CAR)) (group 
VI (ISO+ES)) caused a sharp decrease in the heart rates 
of the ISO injected rats (224±15 vs 283±28; \( P<0.05 \)). Compared to ISO group (ISO+sal) all CAR formulations 
reduced the heart rate; however, the reduction was 
not attained a significant level in some groups (except 
the group VI (ISO+Es)). Additionally, the PR interval 
(also assigned as the PQ interval, which indicates the 
depolarization propagation from the atrium to the 
heart ventricles) significantly was increased in the rats 
treated with CAR–Eud electrosprayed 
nanoformulations (61.4±2.7 msec) compared with rats received ISO alone 
(48.9±4.0 msec; \( P<0.05 \)). Besides, the P amplitude as 
an index of arterial electrophysical activity significantly 
was reduced by CAR-Eud nanosystems administration 
and more interestingly in comparison with ISO group, 
the ST height (a vital parameter for the diagnosis of 
myocardial infarction and myocardial ischemia) was 
also reduced by 40% at the CAR–Eud electrosprayed 
nanoformulations treated group (group VI (ISO+ES)). 
These findings are in good agreement with the results of 
the histopathological evaluation (Figure 5).

The incidence of necrosis and accumulation of 
neutrophils in the heart tissue of experimented rats were 
evaluated by scrutinizing the cross section microscopic 
images of the apex part (Figure 5). The normal control 
group exhibited regular arrangement of the myocardial 
fibers with clear striations. In addition, there was 
no obvious degeneration, necrosis in this group. The 
histological cross sections of ISO treated cardiac tissue 
indicated a severe grade of necrosis at cardiomyocytes 
as well as an increase in the edematous intercellular 
space after hematoxylin and eosin staining (Figure 5B).

It was recognized that treatment with CAR (Figure 5C, 
5d), especially the electrosprayed nanosystems (Figure 
5d), significantly reduced ISO induced necrosis and 
degeneration (\( P<0.05 \)). In the other word, histological 
necrosis and edema scores of the both groups treated 
with the CAR-Eud PM and CAR-Eud electrosprayed 
nanoformulations (1:10; 20 % w/v) were reduced from 
the high pathological changes situation (3.35±0.31, ISO 
group) to moderate state (2.42±0.33 and 2.00±0.41, 
respectively). Consequently, both treated groups 
were protected against ISO-induced necrosis and 
edema, where the protection effect of electrosprayed 
nanoformulation was superior to the PM.

Discussion

Drug delivery mechanisms and drug effectiveness 
are tremendously affected by the morphological 
characteristics and size distribution of the drug particles. 
Besides, the polymer concentration, its nature, chains 
intermolecular interlocking, diffusion rate, solvent 
properties and its coulomb forces, solvent evaporation 
rates as well as several working parameters such as the 
prepared solution feeding rate, operational voltage and 
distance of the grounded surface and nozzle are the vital 
factors can play significant role in the morphological 
characteristics of electrosprayed samples (23, 41, 42). In 
the current study, all the above mentioned parameters 
were kept fixed excluding the ratio of the drug: polymer 
and the total concentration of formulated solutions.

The results revealed that the solutions with low 
concentrations (i.e. 10 % (w/v) at both drug: polymer 
ratios of 1:5 and 1:10) initiated the beads formation 
due to the high surface tension of these formulations 
(26, 31). In other words, high surface tension of the 
solutions at the formulations with low concentration of 
the polymer led to the liquid jet dispersion to separate 
droplets; in contrast, the viscoelastic forces of the 
solutions at the formulations with high concentration of 
the polymer resulted in the fiber formation. Additionally,
Heart failure is one of the major health problems worldwide, caused by the range of heart damages, including pericardium, myocardial and endocardium disorders. The majority of patients with the heart failure suffer from myocardial incompatibility. Anti-adrenergic drugs that block the β adrenergic receptors, are effective candidates for managing this failure (1, 2, 46). CAR is a non-selective β-blocker frequently used to treat the heart failures and hypertension, as long as inhibiting the β-adrenergic receptors, exhibits an antioxidant effect that can lead to increased drug efficacy in the treatment of the cardiac failure (40, 47). Subcutaneous injection of isoproterenol, a beta-adrenergic receptor agonist, triggers myocardial hyperactivity and instant increased heart rate (48-50).

Myocardial infarction initiates the heart rate increment and reduction of perfusion to the organs. Subsequently, the adrenergic system is activated to compensate the systemic hemorrhage. Heart remodeling, necrosis and heart tissue damages occur as a result of the adrenergic system activation. CAR, as a β blocker, prevents activation of the adrenergic system, reduces infarct size, decreases histological damage, regulates the heart rate and inhibits the later consequences of necrosis and heart remodeling. Additionally, the antioxidant activity of CAR neutralizes the reactive oxygen species (ROS) caused by infarction (40, 51, 52). Numerous studies have been conducted to evaluate the effects of various processing parameters and find an appropriate way to improve the in vitro and in vivo characteristics of CAR. Venishetty et al. prepared N-carboxymethyl chitosan coated CAR-loaded solid lipid nanoparticles to increase the oral bioavailability of the drug in the rats (53). In another study, CAR-loaded mucoadhesive chitosan microspheres were developed and efficaciously administered nasally in the rabbits (54). To come to the point, our findings are in good agreement with the previously published works regarding clinical (39, 40) and animal studies (3, 47, 53, 54) of the different formulations of CAR. Therefore, CAR-Eud electrosprayed nanostructures could be interestingly considered as feasible candidates for enhancement of the drug therapeutic effectiveness.

**Conclusion**

Nanobeads and nanofibers of CAR (as a poorly water soluble drug) were effectively formulated using electrospaying technique. The microstructure studies revealed that the drug:polymer ratios (1:5 and 1:10) as well as the total solution concentrations variation 0-20 % (w/v) particularly affected the size and morphology of the nanostructures, where by increasing the solution concentration the beads size increased and the highest concentration led to the fiber formation. DSC and PXRD results showed that the crystalline structure of CAR was transformed to the amorphous form during the electrospaying procedure. Based on the in vitro drug release tests, the electrosprayed nanosystems depicted meaningfully faster drug release rate than the PMs and pure drug. This could be attributed to the amorphization of CAR, homogenous dispersion of the drug into the polymeric matrix and its enhanced specific surface area due to the smaller size of the prepared nanosystems. Furthermore, according to the in vivo results, the electrosprayed nanoformulations reduced the ISO induced elevation of the heart rate and reduced ISO induced necrosis and accumulation of neutrophils in the heart tissue more effective than the pure drug and PM. Our finding revealed that the electrospaying as an economic and one step technique could be
effectively applied for improving the physicochemical characteristics and pharmacologic effect of CAR.

Acknowledgment

The in vitro experiments supported by the Vice Chancellor for Research of Tabriz University of Medical Sciences grant, Tabriz, Iran and the in vivo studies reported in this publication was supported by Elite Researcher Grant Committee under award number (No 943557) from the National Institutes for Medical Research Development (NIMAD), Tehran, Iran.

Conflict of Interest

All authors declared no conflict of interest in present manuscript.

References

1. Cardiovascular disease- World Heart Day 2017 [Internet]. World Health Organization. 2017. Available from: http://www.who.int/cardiovascular_diseases/world-heart-day-2017/en/.
2. Li J, Chen Z, Gao X, Zhang H, Xiong W, Ju J, et al. Meta-analysis comparing metoprolol and carvedilol on mortality benefits in patients with acute myocardial infarction. Am J Cardiol 2017; 120:1479-1486.
3. Patil SS, Roy K, Choudhary B, Mahadik KR. Fabrication of novel GMO/Eudragit E100 nanostructures for enhancing oral bioavailability of carvedilol. Drug Dev Ind Pharm 2016; 42:1300-1307.
4. Janakiraman AK, Sumathi B, Saleem TM, Ramkanth S, Kumar PO, Venkatachalum G. Design and evaluation of carvedilol nanocrystals sustained release tablets. J Appl Pharm Sci 2017; 7:061-068.
5. Aytaz C, Ipek S, Durgun E, Uyar T. Antioxidant electrospun zein nanofibrous web encapsulating quercetin/cyclodextrin inclusion complex. J Mater Sci 2018; 53:1527-1539.
6. Badr-Eldin SM, Ahmed TA, R Ismail H. Aripiprazole-zein nanofibrous web encapsulating quercetin/cyclodextrin system. Mater Sci Eng C 2016; 64:383-390.
7. Jahangiri A, Barzegar-Jalali M, Javadzadeh Y, Hamishehkar H, Adibkia K. Physicochemical characterization of atorvastatin calcium/exetimibe amorphous nano-solid dispersions prepared by electrospaying method. Artif Cells Nanomed Biotechnol 2017; 45:1138-1145.
8. Seo J-W, Hwang K-M, Lee S-H, Kim D-W, Park E-S. Preparation and characterization of adefovir dipivoxil-stearic acid cocrystal with enhanced physicochemical properties. Pharm Dev Technol 2017; 1:10.
9. Zhang Y, Shang Z, Gao C, Du M, Xu S, Song H, et al. Nanoemulsion for solubilization, stabilization, and in vitro release of pterostiberine for oral delivery. AAPS PharmSciTech 2014; 15:1000-1008.
10. Soltani S, Zakeri-Milani P, Barzegar-Jalali M, Jelvehgari M. Design of eudragit RL nanoparticles by nanoemulsion method as carriers for ophthalmic drug delivery of ketotifen fumarate. Iran J Basic Med Sci 2016; 19:550-560.
11. Molael M-A, Osooli-Bostanabad K, Adibkia K, Shokri J, Asnashahi S, Javadzadeh Y. Enhancement of ketocanazole dissolution rate by the liquid solid technique. Acta Pharm 2018; 68:325-336.
12. Hiendrawan S, Widjojokusumo E, Veriansyah B, Tjandraawinata RR. Pharmaceutical salt of carvedilol: polymorphs and physicochemical properties. AAPS PharmSciTech 2017; 18:1417-1425.
13. Adibkia K, Javadzadeh Y, Dastmalchi S, Mohammadi G, Niri FK, Aalaei-Beirami M. Naproxen–eudragit®RS100 nanoparticles: Preparation and physicochemical characterization. Colloids Surf B 2011; 83:155-159.
14. Javadzadeh Y, Ahadi F, Davaran S, Mohammadi G, Sabzevari A, Adibkia K. Preparation and physicochemical characterization of naproxen–PLGA nanoparticles. Colloids Surf B 2018; 161:2747-2760.
15. Samiei M, Farjami A, Dizaj SM, Lotfipour F. Nanoparticles for antimicrobial purposes in endodontics: A systematic review of in vitro studies. Mater Sci Eng C 2016; 58:1260-1278.
16. Song Z, Shi J, Zhang Z, Qi Z, Han S, Cao S. Mesoporous silica-coated gold nanorods with a thermally responsive polymeric cap for near-infrared-activated drug delivery. J Mater Sci 2018; 53:7165-7179.
17. He X, Li Z, Li X, Wang F, Zou L, Wang J, Tang C, et al. Targeted delivery and thermo/pH-controlled release of doxorubicin by novel nanostructures. J Mater Sci 2018; 53:2326-2336.
18. Rai VK, Mishra N, Agrawal AK, Jain S, Yadav NP. Novel drug delivery system: an immense hope for diabetics. Drug Deliv 2016; 23:2371-2390.
19. Gandhi AV, Thipsay P, Kirthivasan B, Squillante E. Adsorption onto mesoporous silica using supercritical fluid technology improves dissolution rate of carbamazepine—a poorly soluble compound. AAPS Pharm Sci Tech 2017; 18:3140-3150.
20. Tonglairoum P, Chaijaroenluk W, Rajanararat T, Ngawhirunpat T, Akkaramongkolporn P, Opanasopit P. Development and characterization of propranolol selective molecular imprinted polymer composite electrospray nanofiber membrane. AAPS Pharm Sci Tech 2013; 14:838-846.
21. Abedinogli D, Charkhpour M, Osooli-Bostanabad K, Selselehjonban S, Emami S, Barzegar-Jalali M, et al. Electrospayed nanosystems of carbamazepine – PVP K30 for enhancing its pharmacologic effects. Iran J Pharm Res 2018; 17:1431-1443.
22. Goh Y-F, Shaker I, Hussain R. Electrospray fibers for tissue engineering, drug delivery, and wound dressing. J Mater Sci 2013; 48:3027-3054.
23. Garjani A, Barzegar-Jalali M, Osooli-Bostanabad K, Ranbar H, Adibkia K. Morphological and physicochemical evaluation of the propranolol HCl–Eudragit® RS100 electrospayed nanoformulations. Artif Cells Nanomed Biotechnol 2018; 46:749-756.
24. Antaya H, Pellerin C. Preparation of the pure poly(e-caprolactone)-urea complex by electrospay. Soft Matter 2011; 9:295-302.
25. Vellayappan MV, Venugopal JR, Ramakrishna S, Ray S, Ismail AF, Mandal M, et al. Electrospinning applications from diagnosis to treatment of diabetes. RSC Adv 2016; 6:83638-83655.
26. Payab S, Davaran S, Tanhaei A, Fayyazi B, Jahangiri A, Farzaneh A, et al. Triaminolone acetonide–Eudragit® RS100 nanoparticles and nanobeads: Morphological and physicochemical characterization. Artif Cells Nanomed Biotechnol 2018; 44:362-369.
27. Roman JA, Reucroft I, Martin RA, Hurtado A, Mao H-Q. Local release of paclitaxel from aligned, electrospun microfibers RS100 nanofibers and nanobeads: Morphological and physicochemical characterization. AAPS PharmSciTech 2016; 17:555-562.
28. Ghaedi Panah N, Alizadeh P, Eftekhari Yekta B, Motakef-Kazemi N. Preparation and in vitro characterization of electrospun bioactive glass nanotubes as mesoporous carriers for ibuprofen. Ceram Int 2016; 42:10935-10942.
29. Payab S, Jafari-Aghdam N, Barzegar-Jalali M, Mohammadi G, Lotfipour F, Gholikhani T, et al. Preparation and physicochemical characterization of the azithromycin–Eudragit RS100 nanobeads and nanoparticles using electrospinning method. J Drug Deliv Sci Technol 2014; 24:505-510.
30. Alduman C, Özgünely I, Kumbasar A. Preparation and characterization of naproxen-loaded electrospun thermoplastic polyurethane nanoparticles as a drug delivery system. Mater Sci Eng C 2016; 64:383-390.
31. Jafari-Aghdam N, Adibkia K, Payab S, Barzegar-Jalali M, Parvizpur A, Mohammadi G, et al. Methylprednisolone
acetate–Eudragit® RS100 electrospuns: Preparation and physicochemical characterization. Artif Cells Nanomed Biotechnol 2016; 44:497-503.
32. Balogh A, Cselkő R, Démuth B, Verreck G, Mensch J, Marosi G, et al. Alternating current electrospinning for preparation of fibrous drug delivery systems. Int J Pharm 2015; 495:75-80.
33. Krstić M, Radiojević M, Stojanović D, Radiojević V, Uskoković P, Ilić S. Formulation and characterization of nanofibers and films with carvedilol prepared by electrospinning and solution casting method. Eur J Pharm Sci 2017; 101:160-166.
34. Balogh A, Farkas B, Faragó K, Farkas A, Wagner I, Vanassche I, et al. Melt-blown and electrospun drug-loaded polymer fiber mats for dissolution enhancement: a comparative study. J Pharm Sci 2015; 104:1767-1776.
35. Huang S, Zhou L, Li M-C, Wu Q, Kojima Y, Zhou D. Preparation and properties of electrospray poly (vinyl pyrrolidone)/cellulose nanocrystal/silver nanoparticle composite fibers. Materials 2016; 9:523.
36. Nagy ZK, Balogh A, Drávavölgyi G, Ferguson J, Pataki H, Vajna B, et al. Solvent-free melt electrospinning for preparation of fast dissolving drug delivery system and comparison with solvent-based electrospin and melt extruded systems. J Pharm Sci 2013; 102:508-517.
37. Bal T, Sengupta S, Murthy PN. Formulation and evaluation of carvedilol microcapsules using Eudragit NE30D and sodium alginate. Braz J Pharm Sci 2013; 49:889-901.
38. Saini R, Singh SK, Verma PR. Evaluation of carvedilol-loaded microsponges with nanometric pores using response surface methodology. Exp Nanos 2014; 9:831-850.
39. Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet 1994; 26:335-346.
40. Feuerstein G, Ruffolo Jr R. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Eur Heart J 1996; 17:24-29.
41. Jahangiri A, Davaran S, Fayaziz B, Tanhaei A, Payab S, Adibkia K. Application of electrospraying as a one-step method for the fabrication of trimcinolone acetone-PGLA nanofibers and nanobeads. Colloids Surf B 2014; 123:219-224.
42. Nguyen DN, Clasen C, Van den Mooter G. Pharmaceutical applications of electrospraying. J Pharm Sci 2016; 105:2601-2620.
43. Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 2006; 62:3-16.
44. Jermain SV, Brough C, Williams RO. Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery – An update. Int J Pharm 2018; 535:379-392.
45. Kajlić S, Vrečer F, Kocbek P. Preparation of poloxamer-based nanofibers for enhanced dissolution of carvedilol. Eur J Pharm Sci 2018; 117:331-340.
46. Wegmann M, Parola L, Bertera FM, Taira CA, Cagel M, Buontempo F, et al. Novel carvedilol paediatric nanomicelle formulation: in-vitro characterization and in-vivo evaluation. J Pharm. Pharmacol 2017; 69:544-553.
47. Liu D, Pan H, He F, Wang X, Li J, Yang X, et al. Effect of particle size on oral absorption of carvedilol nanosuspensions: in vitro and in vivo evaluation. Int J Nanomedicine 2015; 10:6425-6434.
48. Alderman EL, Harrison DC. Myocardial hypertrophy resulting from low dosage isoproterenol administration in rats. Proc Soc Exp Biol Med 1971; 136:268-270.
49. Patel V, Upaganlawar A, Zalawadia R, Balaraman R. Cardioprotective effect of melatonin against isoproterenol induced myocardial infarction in rats: A biochemical, electrocardiographic and histoarchitectural evaluation. Eur J Pharmaco 2010; 644:160-168.
50. Yousefi K, Fathiazad F, Soraya H, Rameshrad M, Maleki-Dizaji N, Garjani A. Marrubium vulgare L. methanolic extract inhibits inflammatory response and prevents cardiomyocyte fibrosis in isoproterenol-induced acute myocardial infarction in rats. Biomolecules 2014; 4:21-27.
51. Bristow MR. Mechanism of Action of Beta-Blocking Agents in Heart Failure. American J Cardiol 1997; 80:26L-40L.
52. Feuerstein G, Yue TL, Ma X, Ruffolo RR. Novel mechanisms in the treatment of heart failure: Inhibition of oxygen radicals and apoptosis by carvedilol. Prog Cardiovasc Dis 1998; 41:17-24.
53. Venishetty VK, Chede R, Komuravelli R, Adepu L, Sistla R, Diwan PV. Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: A novel strategy to avoid intraduodenal administration. Colloids Surf B 2012; 95:1-9.
54. Patil S, Babbar A, Mathur R, Mishra A, Sawant K. Mucoadhesive chitosan microspheres of carvedilol for nasal administration. J Drug Target 2010; 18:321-331.